Fri, February 24, 2023
Thu, February 23, 2023
Wed, February 22, 2023

Matt O"Brien Maintained (TNDM) at Buy with Decreased Target to $50 on, Feb 23rd, 2023

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-50-on-feb-23rd-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication
Matt O"Brien of Piper Sandler, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Buy with Decreased Target from $70 to $50 on, Feb 23rd, 2023.

Matt has made no other calls on TNDM in the last 4 months.

There are 3 other peers that have a rating on TNDM. Out of the 3 peers that are also analyzing TNDM, 2 agree with Matt"s Rating of Hold. Following are those relevant analyst calls for the last 4 months;

Mike Polark of "Wolfe Research" Initiated at Hold on, Thursday, January 26th, 2023
Larry Biegelsen of "Wells Fargo" Upgraded from Sell to Hold and Held Target at $43 on, Tuesday, November 15th, 2022

This is the rating of the analyst that currently disagrees with Matt;

Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $52 on, Friday, November 4th, 2022